{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:25:20Z","timestamp":1782761120435,"version":"3.54.5"},"reference-count":35,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100017727","name":"Fondazione Beretta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Patients with adrenocortical carcinoma (ACC) are frequently on mitotane therapy for a long time period. The drug exerts adrenolytic activity requiring glucocorticoid supplementation, which can be potentially detrimental for bone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To explore whether mitotane with\/without chemotherapy is associated with an increased proportion of morphometric vertebral fractures (VFs) in ACC patients. Secondary objectives were proportion of patients with VF progression, or worsening of the spinal deformity index (SDI) during mitotane therapy; and to explore predictive factors of VF progression and a prognostic role of VF progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Multicenter, retrospective cohort study of patients with ACC who received mitotane alone or in association to chemotherapy, recruited from January 2010 to January 2020 in 2 reference centers in Italy and France.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A significant increase in the frequency of VFs before and after mitotane therapy was seen both in Italian (28.3% vs 47.8%, P = .04) and French (17.8% vs 35.6%, P = .04) series. VF progression was observed in 39.1%, and 28.9% of patients, respectively. Baseline VFs and increased patient body mass index, but not the dose of cortisol supplementation, showed an independent association with VF progression at multivariate analysis. Among the 72 advanced ACC patients, progression of VFs was associated with a poorer survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The administration of mitotane with\/without chemotherapy in ACC patients impairs bone health independently from cortisol supplementation. Appropriate preventive measures to decrease the fracture risk should be implemented in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab899","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T17:02:10Z","timestamp":1639501330000},"page":"e2167-e2176","source":"Crossref","is-referenced-by-count":6,"title":["Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy"],"prefix":"10.1210","volume":"107","author":[{"given":"Deborah","family":"Cosentini","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6922-1934","authenticated-orcid":false,"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Oncology, and Interventional Medicine, Institute Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Lib\u00e8","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Frigerio","sequence":"additional","affiliation":[{"name":"Radiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Deschamps","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Institute Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Zamparini","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Oncology, and Interventional Medicine, Institute Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pedersini","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Valsecchi","sequence":"additional","affiliation":[{"name":"Radiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Maroldi","sequence":"additional","affiliation":[{"name":"Radiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Al Ghuzlan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Oncology, and Interventional Medicine, Institute Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-2851","authenticated-orcid":false,"given":"Massimo","family":"Terzolo","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gasparotti","sequence":"additional","affiliation":[{"name":"Neuroradiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia. ASST Spedali Civili Hospital, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-3582","authenticated-orcid":false,"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Oncology, and Interventional Medicine, Institute Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3956-0043","authenticated-orcid":false,"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"issue":"11","key":"2022041907532777400_CIT0001","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol."},{"issue":"2","key":"2022041907532777400_CIT0002","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ecl.2015.03.001","article-title":"Endocrine tumor board of Gustave Roussy. adrenocortical carcinoma","volume":"44","author":"Baudin","year":"2015","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"23","key":"2022041907532777400_CIT0003","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med."},{"issue":"4","key":"2022041907532777400_CIT0004","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1210\/jc.2016-2894","article-title":"Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma","volume":"102","author":"Berruti","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022041907532777400_CIT0005","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022041907532777400_CIT0006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40618-013-0049-2","article-title":"Management of adrenal cancer: a 2013 update","volume":"37","author":"Terzolo","year":"2014","journal-title":"J Endocrinol Invest."},{"issue":"3","key":"2022041907532777400_CIT0007","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer."},{"issue":"23","key":"2022041907532777400_CIT0008","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med."},{"issue":"4","key":"2022041907532777400_CIT0009","doi-asserted-by":"crossref","first-page":":941","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced Adrenocortical carcinoma: the Brescia experience","volume":"12","author":"Lagan\u00e0","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2022041907532777400_CIT0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","author":"Chortis","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022041907532777400_CIT0011","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1530\/EJE-17-0154","article-title":"Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects","volume":"177","author":"Mazziotti","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022041907532777400_CIT0012","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00002281-200307000-00013","article-title":"Mechanisms of glucocorticoid-induced osteoporosis","volume":"15","author":"Canalis","year":"2003","journal-title":"Curr Opin Rheumatol."},{"issue":"29","key":"2022041907532777400_CIT0013","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.20.00434","article-title":"Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies","volume":"38","author":"Dalla Volta","year":"2020","journal-title":"J Clin Oncol."},{"key":"2022041907532777400_CIT0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000443866","article-title":"Skeletal fragility in endogenous hypercortisolism","volume":"46","author":"Mazziotti","year":"2016","journal-title":"Front Horm Res."},{"issue":"2","key":"2022041907532777400_CIT0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989","volume":"7","author":"Cooper","year":"1992","journal-title":"J Bone Miner Res."},{"key":"2022041907532777400_CIT0016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bone.2017.01.013","article-title":"Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study","volume":"97","author":"Pedersini","year":"2017","journal-title":"Bone."},{"issue":"9","key":"2022041907532777400_CIT0017","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4065\/mcp.2010.0082","article-title":"Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women","volume":"85","author":"Adachi","year":"2010","journal-title":"Mayo Clin Proc."},{"issue":"2","key":"2022041907532777400_CIT0018","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00330-012-2622-z","article-title":"Review of radiological scoring methods of osteoporotic vertebral fractures for clinical and research settings","volume":"23","author":"Oei","year":"2013","journal-title":"Eur Radiol."},{"issue":"9","key":"2022041907532777400_CIT0019","doi-asserted-by":"crossref","first-page":"e1911080","DOI":"10.1001\/jamanetworkopen.2019.11080","article-title":"Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy","volume":"2","author":"Pedersini","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2022041907532777400_CIT0020","doi-asserted-by":"crossref","first-page":"e10440","DOI":"10.1002\/jbm4.10440","article-title":"The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy","volume":"5","author":"Monteverdi","year":"2021","journal-title":"JBMR Plus."},{"issue":"9","key":"2022041907532777400_CIT0021","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2022041907532777400_CIT0022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00198-008-0832-7","article-title":"Spinal deformity index (SDI) is a good predictor of incident vertebral fractures","volume":"20","author":"Kerkeni","year":"2009","journal-title":"Osteoporos Int."},{"issue":"5","key":"2022041907532777400_CIT0023","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-19-0026","article-title":"Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study","volume":"180","author":"Berruti","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022041907532777400_CIT0024","doi-asserted-by":"crossref","first-page":"221.e1","DOI":"10.1016\/j.amjmed.2015.09.020","article-title":"Vertebral fractures: clinical importance and management","volume":"129","author":"Kendler","year":"2016","journal-title":"Am J Med."},{"issue":"6B","key":"2022041907532777400_CIT0025","first-page":"2871","article-title":"Biochemical picture of bone metabolism in breast cancer patients with bone metastases","volume":"15","author":"Berruti","year":"1995","journal-title":"Anticancer Res."},{"issue":"12","key":"2022041907532777400_CIT0026","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00198-005-2023-0","article-title":"The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women","volume":"16","author":"Fechtenbaum","year":"2005","journal-title":"Osteoporos Int."},{"issue":"12","key":"2022041907532777400_CIT0027","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"ESMO guidelines committee. electronic address: clinicalguidelines@esmo.org. Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol."},{"issue":"2","key":"2022041907532777400_CIT0028","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bone.2013.07.011","article-title":"Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab","volume":"56","author":"Genant","year":"2013","journal-title":"Bone."},{"issue":"3","key":"2022041907532777400_CIT0029","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00223-018-00512-x","article-title":"Scientific advisory board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the committees of scientific advisors and national societies of the International Osteoporosis Foundation (IOF). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"104","author":"Kanis","year":"2019","journal-title":"Calcif Tissue Int."},{"issue":"5","key":"2022041907532777400_CIT0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ajcn\/82.5.923","article-title":"Obesity in older adults: technical review and position statement of the American society for nutrition and NAASO, the obesity society","volume":"82","author":"Villareal","year":"2005","journal-title":"Am J Clin Nutr."},{"issue":"1","key":"2022041907532777400_CIT0031","first-page":"45","article-title":"Determinants of total body and regional bone mineral density in normal postmenopausal women\u2013a key role for fat mass","volume":"75","author":"Reid","year":"1992","journal-title":"J Clin Endocrinol Metab."},{"key":"2022041907532777400_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nutres.2016.12.010","article-title":"Obesity is a concern for bone health with aging","volume":"39","author":"Shapses","year":"2017","journal-title":"Nutr Res."},{"issue":"4","key":"2022041907532777400_CIT0033","first-page":"873","article-title":"DDT- and DDE-induced disruption of ovarian steroidogenesis in prepubertal porcine ovarian follicles: a possible interaction with the main steroidogenic enzymes and estrogen receptor beta","volume":"58","author":"W\u00f3jtowicz","year":"2007","journal-title":"J Physiol Pharmacol."},{"issue":"10","key":"2022041907532777400_CIT0034","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/jbmr.4100","article-title":"CaMos research group. a risk assessment tool for predicting fragility fractures and mortality in the elderly","volume":"35","author":"Tran","year":"2020","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2022041907532777400_CIT0035","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","article-title":"Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications","volume":"111","author":"Shao","year":"2013","journal-title":"BJU Int."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab899\/42235351\/dgab899.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/5\/e2167\/43386514\/dgab899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/5\/e2167\/43386514\/dgab899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:58:15Z","timestamp":1650355095000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/5\/e2167\/6461116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,12,14]]},"published-print":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab899","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,12,14]]}}}